MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1

Cancer Science

Volumn 101, Issue 9, 2010, Pages 1997-2004

  Chai, Guolin ^a   Liu, Ning ^a   Ma, Junrong ^a   Li, Hua ^b   Oblinger, Janet L ^c   Prahalad, Agasanur K ^a   Gong, Meng ^a   Chang, Long Sheng ^c   Wallace, Margaret ^b   Muir, David ^b   Guha, Abhijit ^d,e   Phipps, Roger J ^a   Hock, Janet M ^a   Yu, Xijie ^a  

^a Maine Institute for Human Genetics & Health   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d TORONTO WESTERN HOSPITAL   (Canada)

^e HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 10B; NEUROFIBROMIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NEUROECTODERM TUMOR; NEUROFIBROMA; NEUROFIBROMATOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHWANN CELL; UPREGULATION;

3' UNTRANSLATED REGIONS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MICRORNAS; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, ANTISENSE; SCHWANN CELLS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 77955956247     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01616.x     Document Type: Article

References (49)

1. Riccardi VM, Womack JE, Jacks T. Neurofibromatosis and related tumors. Natural occurrence and animal models. Am J Pathol 1994, 145:994-1000.
2. Gutmann DH, Aylsworth A, Carey JC. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997, 278:51-7.
3. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002, 39:311-4.
4. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986, 57:2006-21.
5. Bollag G, McCormick F. Ras regulation. NF is enough of GAP. Nature 1992, 356:663-4.
6. Kluwe L, Friedrich R, Mautner VF. Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. Genes Chromosomes Cancer 1999, 24:283-5.
7. Rutkowski JL, Wu K, Gutmann DH, Boyer PJ, Legius E. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet 2000, 9:1059-66.
8. Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat Genet 1993, 3:122-6.
9. Easton DF, Ponder MA, Huson SM, Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet 1993, 53:305-13.
10. Metheny LJ, Cappione AJ, Skuse GR. Genetic and epigenetic mechanisms in the pathogenesis of neurofibromatosis type I. J Neuropathol Exp Neurol 1995, 54:753-60.
11. Griesser J, Kaufmann D, Maier B, Mailhammer R, Kuehl P, Krone W. Post-transcriptional regulation of neurofibromin level in cultured human melano-cytes in response to growth factors. J Invest Dermatol 1997, 108:275-80.
12. Cappione AJ, French BL, Skuse GR. A potential role for NF1 mRNA editing in the pathogenesis of NF1 tumors. Am J Hum Genet 1997, 60:305-12.
13. Skuse GR, Cappione AJ. RNA processing and clinical variability in neurofibromatosis type I (NF1). Hum Mol Genet 1997, 6:1707-12.
14. Kaufmann D, Bartelt B, Hoffmeyer S, Muller R. Posttranslational regulation of neurofibromin content in melanocytes of neurofibromatosis type 1 patients. Arch Dermatol Res 1999, 291:312-7.
15. Hoffmeyer S, Assum G, Griesser J, Kaufmann D, Nurnberg P, Krone W. On unequal allelic expression of the neurofibromin gene in neurofibromatosis type 1. Hum Mol Genet 1995, 4:1267-72.
16. Skuse GR, Cappione AJ, Sowden M, Metheny LJ, Smith HC. The neurofibromatosis type I messenger RNA undergoes base-modification RNA editing. Nucleic Acids Res 1996, 24:478-85.
17. Li Y, O'Connell P, Breidenbach HH. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics 1995, 25:9-18.
18. Haeussler J, Haeusler J, Striebel AM. Tumor antigen HuR binds specifically to one of five protein-binding segments in the 3'-untranslated region of the neurofibromin messenger RNA. Biochem Biophys Res Commun 2000, 267:726-32.
19. Lim LP, Lau NC, Garrett-Engele P. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-73.
20. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006, 94:776-80.
21. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2007, 96(Suppl):R40-4.
22. Rouhi A, Mager DL, Humphries RK, Kuchenbauer F. MiRNAs, epigenetics, and cancer. Mamm Genome 2008, 19:517-25.
23. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol 2009, 174:1131-8.
24. Jacob A, Lee TX, Neff BA, Miller S, Welling B, Chang LS. Phosphatidylinositol 3-kinase/AKT pathway activation in human vestibular schwannoma. Otol Neurotol 2008, 29:58-68.
25. Muir D, Neubauer D, Lim IT, Yachnis AT, Wallace MR. Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am J Pathol 2001, 158:501-13.
26. Miller SJ, Rangwala F, Williams J. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006, 66:2584-91.
27. Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res 2006, 12:5533-42.
28. Miki T, Yano S, Hanibuchi M, Sone S. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. Oncol Res 2000, 12:209-17.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-8.
30. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-8.
31. Fletcher JA, Kozakewich HP, Hoffer FA. Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors. N Engl J Med 1991, 324:436-42.
32. Garzon R, Garofalo M, Martelli MP. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008, 105:3945-50.
33. Eis PS, Tam W, Sun L. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci U S A 2005, 102:3627-32.
34. Tavazoie SF, Alarcon C, Oskarsson T. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-52.
35. Johnson SM, Grosshans H, Shingara J. RAS is regulated by the let-7 microRNA family. Cell 2005, 120:635-47.
36. Subramanian S, Thayanithy V, West RB. Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol 2009, 220:58-70.
37. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994, 7:353-61.
38. Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol 1995, 15:6443-53.
39. Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Lebowitz PF, Der CJ. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 1995, 10:2289-96.
40. Qiu RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature 1995, 374:457-9.
41. Qiu RG, Chen J, McCormick F, Symons M. A role for Rho in Ras transformation. Proc Natl Acad Sci U S A 1995, 92:11781-5.
42. Sahai E, Ishizaki T, Narumiya S, Treisman R. Transformation mediated by RhoA requires activity of ROCK kinases. Curr Biol 1999, 9:136-45.
43. DeClue JE, Papageorge AG, Fletcher JA. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992, 69:265-73.
44. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992, 356:713-5.
45. Bollag G, Clapp DW, Shih S. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996, 12:144-8.
46. Feldkamp MM, Angelov L, Guha A. Neurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathway. Surg Neurol 1999, 51:211-8.
47. Ingram DA, Hiatt K, King AJ. Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med 2001, 194:57-69.
48. Levy P, Ripoche H, Laurendeau I. Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Clin Cancer Res 2007, 13:398-407.
49. Park SM, Shell S, Radjabi AR. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle 2007, 6:2585-90.